Literature DB >> 10225340

Subjective experience and mental side-effects of antipsychotic treatment.

J Gerlach1, E B Larsen.   

Abstract

Many schizophrenic patients have a negative attitude towards antipsychotic drugs. This attitude is not only due to lack of insight into the disease, lack of recognition of the beneficial effects of the drugs, and to objective side-effects. The negative attitude is to a high degree due to mental side-effects and a sceptical opinion about antipsychotic medication in general. In a study of 53 chronic schizophrenic out-patients receiving maintenance depot antipsychotic treatment, we found that 60% were positive about the treatment, 32% were ambivalent and 8% had a negative attitude. Only 60% complained of side-effects, even though 94% had objective side-effects. Mental side-effects such as subjective akathisia, dysphoria and emotional indifference were most often observed by the patients, while hypokinesia and hyperkinesia were least noticed by them, but most often observed by the physician. No correlation was found between the patients' subjective assessment of their quality of life and the degree of psychosis and side-effects. With the new atypical antipsychotics this situation seems to be changing. These new drugs are primarily characterized by a lower level of motor extrapyramidal side-effects (EPS), and with fewer motor EPS, fewer mental EPS can be expected. In recent studies comparing the new antipsychotics with haloperidol, better effects have been observed with regard to negative symptoms and depression, and this may at least in part be a reflection of a lower level of mental side-effects of the atypical antipsychotics. This improved clinical profile of new antipsychotics is extremely valuable in the context of an integrated treatment in schizophrenia, consisting of early intervention, psychosocial rehabilitation and family/patient psycho-education.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225340     DOI: 10.1111/j.1600-0447.1999.tb05990.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  16 in total

Review 1.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

2.  The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment.

Authors:  Michael E Ballard; Ana M Basso; Kelly B Gallagher; Kaitlin E Browman; Gerard B Fox; Karla U Drescher; Gerhard Gross; Michael W Decker; Lynne E Rueter; Min Zhang
Journal:  Psychopharmacology (Berl)       Date:  2006-11-09       Impact factor: 4.530

3.  The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression.

Authors:  Martino Belvederi Murri; Mario Amore; Pietro Calcagno; Matteo Respino; Valentina Marozzi; Mattia Masotti; Michele Bugliani; Marco Innamorati; Maurizio Pompili; Silvana Galderisi; Mario Maj
Journal:  Schizophr Bull       Date:  2016-04-11       Impact factor: 9.306

Review 4.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  An approach to maximizing treatment adherence of children and adolescents with psychotic disorders and major mood disorders.

Authors:  Robin Edward Gearing; Irfan A Mian
Journal:  Can Child Adolesc Psychiatr Rev       Date:  2005-11

6.  Development of the My Medicines and Me (M3Q) side effect questionnaire for mental health patients: a qualitative study.

Authors:  Deena M Ashoorian; Rowan M Davidson; Daniel J T Rock; Liza J Seubert; Rhonda M Clifford
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

7.  Differential Medication Attitudes to Antihypertensive and Mood Stabilizing Agents in response to an Automated Text-Messaging Adherence Enhancement Intervention.

Authors:  Peter Klein; Michelle E Aebi; Martha Sajatovic; Colin Depp; David Moore; Carol Blixen; Jennifer B Levin
Journal:  J Behav Cogn Ther       Date:  2020-07-17

Review 8.  The impact of subjective well-being under neuroleptic treatment on compliance and remission.

Authors:  Walter de Millas; Martin Lambert; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

9.  Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.

Authors:  Ariel Berger; John Edelsberg; Kafi N Sanders; Jose Ma J Alvir; Marko A Mychaskiw; Gerry Oster
Journal:  BMC Psychiatry       Date:  2012-08-02       Impact factor: 3.630

Review 10.  Patient and family attitudes toward schizophrenia treatment.

Authors:  Farzin Irani; Mary Dankert; Steven J Siegel
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.